Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03113409 · ClinicalTrials.gov registry record · Phase 2
Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT03113409: Clinical Trial Phase 2 study, sponsored by New York State Psychiatric Institute.
NCT03113409 is a Phase 2 study that was terminated before completion, run by New York State Psychiatric Institute. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03113409, a Phase 2 study, was terminated before completion, sponsored by New York State Psychiatric Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The study will enroll 30 opioid-dependent participants into an open-label pilot outpatient study of methods to facilitate induction and stabilization onto XR-NTX. There will be three different methods of XR-NTX induction using increasing doses of oral naltrexone and buprenophine.
Primary Outcome
Percentage of patient who initiated Procedure 1 and completed the study receiving the 2nd injection of XR-NTX
Interventions
- DRUG Buprenorphine
- DRUG Naltrexone
- DRUG Vivitrol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2020-12-01 |
| Phase | Phase 2 |
Why NCT03113409 stopped before completion
NCT03113409 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 3 interventions - of which Buprenorphine is the first listed.
NCT03113409 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03113409 about?
NCT03113409 is a clinical study titled "Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol". The study will enroll 30 opioid-dependent participants into an open-label pilot outpatient study of methods to facilitate induction and stabilization onto XR-NTX. There will be three different methods of XR-NTX induction using increasing doses of oral naltrexone and buprenophine.
What is the current status of trial NCT03113409?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2017-06-01. Estimated completion is 2020-12-01.
What interventions are being tested in trial NCT03113409?
The interventions under investigation include: Buprenorphine (DRUG), Naltrexone (DRUG), Vivitrol (DRUG).
Who is sponsoring clinical trial NCT03113409?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03113409's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI